LIGHTRICKS
20.8.2024 14:02:26 CEST | Business Wire | Press release
Lightricks, the AI innovators behind Facetune, Videoleap, Photoleap and Popular Pays, announced today that LTX Studio beta, the first AI-driven storyboarding and prototyping platform, is now open to the public. The platform, designed for creative film and marketing professionals, offers real-time, intuitive generative and editing solutions. This announcement includes new features that push the boundaries of visual storytelling, such as increased character and frame control and multi-user collaboration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240820994937/en/
The LTX Studio platform integrates proprietary AI research from Lightricks engineers with the latest licensed and open-source generative AI models, redefining the creative process. It streamlines video production planning and execution, empowering a wide range of creative professionals—from individual filmmakers to large production companies and advertising agencies—to develop, visualize, storyboard, and pitch their creative concepts into fully crafted film and video projects with unprecedented efficiency and control.
“Releasing LTX Studio to everyone demonstrates our ongoing commitment to the future of video creation through innovative AI-driven tools and our belief in generative AI as a powerful market changer," said Zeev Farbman, CEO and co-founder of Lightricks. “We’ve worked closely with our design partners and creator community to ensure our platform meets their diverse needs better than anything else on the market. We remain committed to exploring new technology and enhancing LTX Studio’s capabilities.”
LTX Studio’s suite of AI features has been refined based on technical and creative feedback from our creative community of more than 35,000 members. The latest updates focus on:
- Enhanced Collaboration: The new Collaboration feature enables creative teams to work together more efficiently with live edit views. LTX Studio plans to release additional collaborative tools, such as commenting and suggestion capabilities, soon.
- Character Acting: LTX Studio now syncs realistic voices with lip movements for any character, allowing users to customize facial gestures and dialogues by referencing real human videos. Users can generate voice from text using AI or upload their original voice files. Future updates will include voice switching for character dialogue and complete scene editing with dialogues.
- Generation Control: Users can now enjoy more control and accuracy in creating their wanted frames and desired motion. Frame Creator lets users craft frames using prompts and scribbles. Keyframe Control generates frames between defined start and end points.
Case Study: Recently, financial services company eToro used LTX Studio to create an AI-generated advertisement that aired during the Paris Olympics. This showcased LTX Studio’s ability to produce high-quality, realistic video content, demonstrating how brands can easily leverage LTX Studio to create compelling visual stories.
Pricing: LTX Studio now offers a tiered pricing model. Users can experience the platform for free with limited generative AI capability, or select from a range of plans based on their monthly generative time needs. Custom plans with premium features are available for enterprises and larger organizations and teams.
Lightricks is embarking on a prolific roadmap for LTX Studio leading into 2025, focusing on leveraging AI to innovate the visual storytelling experience and fuel creativity for professional creators globally. To experience LTX Studio today, join at LTX.Studio.
About Lightricks
Lightricks, an AI-first company, is revolutionizing how visual content is created. With a mission to bridge the gap between imagination and creation, Lightricks is dedicated to bringing cutting-edge technology to the creative and business spaces.
Our AI photo and video generation models, which power our apps and platforms including Facetune, Photoleap, Videoleap, and LTX Studio, allow creators and brands to leverage the latest research breakthroughs, offering endless control over their creative potential. Our influencer marketing platform, Popular Pays, provides creators the ability to monetize their work and offers brands opportunities to scale their content through tailored creator partnerships.
Founded in 2013, Lightricks is backed by prominent investors including Goldman Sachs Growth Equity, Insight Partners and Viola Ventures, who share Lightricks’ enduring commitment to driving the future of content creation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820994937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom